Rhythm Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Rhythm Pharmaceuticals's estimated annual revenue is currently $5.9M per year.
- Rhythm Pharmaceuticals received $41.0M in venture funding in February 2017.
- Rhythm Pharmaceuticals's estimated revenue per employee is $30,051
- Rhythm Pharmaceuticals's total funding is $637.7M.
Employee Data
- Rhythm Pharmaceuticals has 196 Employees.
- Rhythm Pharmaceuticals grew their employee count by 23% last year.
Rhythm Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.8M | 73 | -39% | $107.3M | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $3.1M | 26 | 63% | N/A | N/A |
#4 | $29.6M | 125 | 18% | $351M | N/A |
#5 | $15.8M | 84 | -18% | $312.8M | N/A |
#6 | $0.5M | 7 | 17% | N/A | N/A |
#7 | $235M | 269 | -43% | $340.9M | N/A |
#8 | $2.2M | 28 | 4% | N/A | N/A |
#9 | $0.6M | 10 | -9% | N/A | N/A |
#10 | $0.5M | 9 | 29% | N/A | N/A |
What Is Rhythm Pharmaceuticals?
Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity. Rhythm's lead product candidate is setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist. Rhythm supports The Genetic Obesity Project (GeneticObesity.com) and the GO-ID Genotyping Study (GeneticObesityID.com).
keywords:Biotechnology,Enterprise Software,Healthcare,Human Resources Hr,Pharmaceuticals
$637.7M
Total Funding
196
Number of Employees
$5.9M
Revenue (est)
23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Rhythm Pharmaceuticals News
Needham & Company LLC dropped their price target on Rhythm Pharmaceuticals from $50.00 to $45.00 and set a buy rating on the stock in a...
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company...
Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity.
-- New subgroup analysis of Phase 3 data show setmelanotide achieved statistically significant weight loss and hunger reduction compared with placebo at 14 weeks in patients with Bardet-Biedl syndrome -- -- Efficacy results from complete topline analyses of Rhythm’s Phase 2 Basket Study show wei ...
→ Rhythm Pharmaceuticals $RYTM CEO Keith Gottesdiener is planning to stay at the helm until the biotech completes its new drug application, and then head out. He says it’s the right time to hand over the reins and the company plans to organize a search for his replacement. His ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $46.9M | 196 | 9% | N/A |
#2 | $32M | 196 | 96% | N/A |
#3 | $35M | 196 | 2% | N/A |
#4 | $47.1M | 197 | 10% | N/A |
#5 | $46.7M | 197 | 19% | N/A |
Rhythm Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2010-09-09 | $40.0M | A | MPM Capital, New Enterprise Associates | Article |
| 2012-06-05 | $9.5M | Undisclosed | Article | |
| 2012-06-14 | $25.0M | B | MPM Capital, New Enterprise Associates | Article |
| 2012-11-28 | $8.0M | Undisclosed | Pfizer Venture Investments | Article |
| 2017-02-17 | $41.0M | Undisclosed | Multiple | Article |